{
    "clinical_study": {
        "@rank": "154644", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1 - Fusilev - 20 doses", 
                "arm_group_type": "Experimental", 
                "description": "5 mg/m2 QID (6 hours apart) starting on Days 2 and 16 (24 hours after Folotyn dose) for a total of 20 doses in a 28-day cycle\nDays 2 and 16: 4 doses/day\nDays 3 and 17: 4 doses/day\nDays 4 and 18: 2 doses/day\nFolotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
            }, 
            {
                "arm_group_label": "Cohort 2 - Fusilev - 12 doses", 
                "arm_group_type": "Experimental", 
                "description": "5 mg/m2 BID 8 hours apart on Days 2, 3, 4, 16, 17, and 18 for a total of 12 doses in a 28-day cycle.\nFusilev dose to start 24 hours after Folotyn dose.\nFolotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
            }, 
            {
                "arm_group_label": "Cohort 3 - Fusilev - 8 doses", 
                "arm_group_type": "Experimental", 
                "description": "5 mg/m2 BID 8 hours apart on Days 2, 3, 16, and 17 for a total of 8 doses in a 28-day cycle.\nFusilev dose to start 24 hours after Folotyn dose.\nFolotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
            }, 
            {
                "arm_group_label": "Cohort 4 - Fusilev - 4 doses", 
                "arm_group_type": "Experimental", 
                "description": "5 mg/m2 BID 8 hours apart on Days 2 and 16 for a total of 4 doses in a 28-day cycle.\nFusilev dose to start 24 hours after Folotyn dose.\nFolotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
            }, 
            {
                "arm_group_label": "Cohort 5 - Fusilev - 2 doses", 
                "arm_group_type": "Experimental", 
                "description": "5 mg/m2 once on Days 2 and 16 for a total of 2 doses in a 28-day cycle\nFolotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine the optimal dose and schedule of Fusilev to prevent or reduce Folotyn-related\n      Grade 3 or higher oral mucositis in patients with Non-Small Cell Lung Cancer."
        }, 
        "brief_title": "Phase 1 Study of Fusilev\u00ae to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn\u00ae", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Mucositis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label, uncontrolled, nonrandomized, multicenter, dose-finding, single-arm,\n      Phase 1 study primarily to determine the optimal dose and schedule of Fusilev to prevent or\n      reduce Folotyn-related Grade 3 or higher oral mucositis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 18 years of age\n\n          -  Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC) after at least one line of\n             therapy\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2\n\n          -  Histologically or cytologically confirmed Stage III B/IV NSCLC\n\n          -  Adequate hematological, hepatic, and renal function\n\n          -  Available during the first 8 weeks of the study treatment period to visit the clinic\n             for oral Mucositis assessments on scheduled days\n\n        Exclusion Criteria:\n\n          -  Active concurrent malignancy. If there is a history of prior malignancies other than\n             those exceptions listed above, the patient must be disease-free for at least 5 years\n\n          -  Congestive heart failure\n\n          -  Uncontrolled hypertension\n\n          -  Known human immunodeficiency virus (HIV)-positive diagnosis\n\n          -  Previous exposure to Pralatrexate\n\n          -  Pregnant or breast-feeding women\n\n          -  Major surgery within 14 days of enrollment\n\n          -  Active uncontrolled infection, underlying medical condition, or other serious illness\n             that would impair the ability of the patient to receive protocol treatment\n\n          -  Symptomatic central nervous system (CNS) metastases or lesions for which treatment is\n             required. Patients who received prophylactic CNS treatment are eligible"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01820091", 
            "org_study_id": "SPI-FUS-12-103"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1 - Fusilev - 20 doses", 
                    "Cohort 2 - Fusilev - 12 doses", 
                    "Cohort 3 - Fusilev - 8 doses", 
                    "Cohort 4 - Fusilev - 4 doses", 
                    "Cohort 5 - Fusilev - 2 doses"
                ], 
                "description": "A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.", 
                "intervention_name": "Folotyn", 
                "intervention_type": "Drug", 
                "other_name": "Pralatrexate"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1 - Fusilev - 20 doses", 
                    "Cohort 2 - Fusilev - 12 doses", 
                    "Cohort 3 - Fusilev - 8 doses", 
                    "Cohort 4 - Fusilev - 4 doses", 
                    "Cohort 5 - Fusilev - 2 doses"
                ], 
                "description": "Fusilev will be administered either four times a day (QID) (6 hours apart, \u00b110 minutes), twice a day (BID) (8 hours apart, \u00b110 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.", 
                "intervention_name": "Fusilev", 
                "intervention_type": "Drug", 
                "other_name": "Levoleucovorin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Leucovorin", 
                "Levoleucovorin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 3, 2013", 
        "number_of_arms": "5", 
        "official_title": "An Open Label, Multicenter, Dose Finding, Single Arm, Phase 1 Study of Fusilev\u00ae (Levoleucovorin) to Prevent or Reduce Mucositis in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Receiving Folotyn\u00ae (Pralatrexate)", 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The study period will begin on the first day of Folotyn treatment (Day 1). Folotyn will be administered intravenously (IV) at a dose of 190 mg/m2 on Days 1 and 15 in a 28-day treatment cycle. Twenty-four hours after the Folotyn dose, Fusilev will be administered either four times a day (QID) (6 hours apart, \u00b110 minutes), twice a day (BID) (8 hours apart, \u00b110 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned. Within a given cohort, Fusilev will be administered at the same dose and schedule after each Folotyn dose for the duration of the study.", 
            "measure": "Optimal dose and Schedule of Fusilev to prevent or reduce Oral Mucositis", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01820091"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Impact of Fusilev on the number of Folotyn-related dose modifications secondary to oral mucositis", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 8 weeks"
            }, 
            {
                "measure": "Impact of Fusilev on the frequency of Oral Mucositis", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 8 weeks"
            }, 
            {
                "measure": "Impact of Fusilev on use of Analgesics for Oral Mucositis", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 8 weeks"
            }, 
            {
                "measure": "Impact of Fusilev on number of Folotyn doses delivered", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 8 weeks"
            }
        ], 
        "source": "Spectrum Pharmaceuticals, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Spectrum Pharmaceuticals, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}